Skip to main content

Table 5 Prognostic value of CTC and DTC detection in patients subgrouped by ER, PR, and HER2 status (Bold: P > 0.05)

From: The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients

   

ER

PR

HER2

   

Positive

Negative

Positive

Negative

Positive

Negative

Metastasis-free survival

 

HR

2.2

2.2

2.6

2.3

1.2

2.9

 

CTC status

95% CI

1.0 to 4.6

1.2 to 4.3

1.2 to 5.9

1.3 to 4.2

0.5 to 2.9

1.6 to 5.1

  

P-value

0.037

0.015

0.018

0.006

0.691

< 0.001

  

HR

2.1

1.1

1.6

1.5

1.2

1.6

 

DTC status

95% CI

1.2 to 3.9

0.5 to 2.4

0.7 to 3.6

0.8 to 2.9

0.5 to 3.0

0.9 to 2.9

  

P-value

0.015

0.902

0.243

0.179

0.712

0.103

Breast cancer specific survival

 

HR

1.9

2.4

2.0

2.8

1.4

2.9

 

CTC status

95% CI

0.7 to 4.8

1.2 to 4.6

0.7 to 5.6

1.5 to 5.2

0.5 to 3.4

1.5 to 5.5

  

P-value

0.180

0.01

0.200

0.001

0.504

0.001

  

HR

2.9

1.1

1.4

2.0

1.6

1.7

 

DTC status

95% CI

1.4 to 5.7

0.5 to 2.5

0.5 to 3.9

1.1 to 3.8

0.7 to 4.0

0.9 to 3.3

  

P-value

0.003

0.832

0.560

0.025

0.268

0.098

  1. CI, confidence interval; CTC, circulating tumour cell; DTC, disseminated tumour cell; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor